Eli Lilly And Company (LLY): Today's Featured Health Care Winner

Eli Lilly and Company was a winner within the health care sector, rising $1.56 (3.1%) to $52.55 on heavy volume
By TheStreet Wire ,

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Eli Lilly and Company

(

LLY

) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.6%. By the end of trading, Eli Lilly and Company rose $1.56 (3.1%) to $52.55 on heavy volume. Throughout the day, 8,892,954 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5,376,800 shares. The stock ranged in a price between $51.75-$52.68 after having opened the day at $52.05 as compared to the previous trading day's close of $50.99. Other companies within the Health Care sector that increased today were:

Cormedix

(

CRMD

), up 14.5%,

ImmunoCellular Therapeutics

(

IMUC

), up 13.0%,

Transition Therapeutics

(

TTHI

), up 11.8% and

Illumina

(

ILMN

), up 10.6%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $57.0 billion and is part of the drugs industry. Shares are up 2.7% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Eli Lilly and Company

as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front,

Mast Therapeutics

(

MSTX

), down 35.9%,

Sarepta Therapeutics

(

SRPT

), down 18.9%,

Neostem

(

NBS

), down 15.6% and

OncoMed Pharmaceuticals

(

OMED

), down 12.2% , were all laggards within the health care sector with

Vertex Pharmaceuticals

(

VRTX

) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

Loading ...